BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating

finance.yahoo.com/news/bofa-hikes-ascendis-pharma-price-145050175.html

In This Article:
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best 52-week high stocks to buy, according to analysts. On June 9, BofA analyst Tazeen Ahmad reiterated a 'Buy' rating on the stock and raised the price target to $216 from $201.
A biopharmaceutical scientist wearing a lab…

This story appeared on finance.yahoo.com, 2025-06-16 14:50:50.
The Entire Business World on a Single Page. Free to Use →